- Home
- HXL vs RNA Comparison
HXL vs RNA Comparison
Compare HXL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HXL
- RNA
- Stock Information
- Founded
- HXL 1946
- RNA 2012
- Country
- HXL United States
- RNA United States
- Employees
- HXL N/A
- RNA N/A
- Industry
- HXL Major Chemicals
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- HXL Industrials
- RNA Health Care
- Exchange
- HXL Nasdaq
- RNA Nasdaq
- Market Cap
- HXL 4.4B
- RNA 3.6B
- IPO Year
- HXL N/A
- RNA 2020
- Fundamental
- Price
- HXL $57.30
- RNA $29.17
- Analyst Decision
- HXL Hold
- RNA Strong Buy
- Analyst Count
- HXL 10
- RNA 14
- Target Price
- HXL $61.20
- RNA $68.00
- AVG Volume (30 Days)
- HXL 1.1M
- RNA 1.4M
- Earning Date
- HXL 07-24-2025
- RNA 08-08-2025
- Dividend Yield
- HXL 1.19%
- RNA N/A
- EPS Growth
- HXL 29.12
- RNA N/A
- EPS
- HXL 1.51
- RNA N/A
- Revenue
- HXL $1,887,200,000.00
- RNA $8,927,000.00
- Revenue This Year
- HXL $1.37
- RNA N/A
- Revenue Next Year
- HXL $11.15
- RNA $156.80
- P/E Ratio
- HXL $37.96
- RNA N/A
- Revenue Growth
- HXL 4.63
- RNA N/A
- 52 Week Low
- HXL $45.28
- RNA $21.51
- 52 Week High
- HXL $71.05
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- HXL 62.10
- RNA 43.92
- Support Level
- HXL $56.20
- RNA $27.71
- Resistance Level
- HXL $57.66
- RNA $30.52
- Average True Range (ATR)
- HXL 1.26
- RNA 1.34
- MACD
- HXL 0.13
- RNA -0.20
- Stochastic Oscillator
- HXL 79.58
- RNA 36.40
About HXL Hexcel Corporation
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and their respective subcontractors.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.